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therapy for tuberculosis based on a well-organized clinic service for a
year, is virtually as effective as sanatorium treatment for the same
period, not only in the immediate therapeutic response in terms of
overall radiographic improvement, cavity closure and sputum con-
version (Tuberculosis Chemotherapy Centre, Madras, 1959) but also
in the likelihood of relapse in a subsequent 4-year period of follow-up
(Dawson et al, 1966). Further, principally owing to the rapid sputum
conversion of patients receiving effective chemotherapy there was no
increased risk of contracting the disease to close family contacts of
the patients treated at home, the main risk to them being before
treatment had begun (Andrews et al,1960; Kamat et al, 1966).
These studies also clearly showed that the traditionally held virtues
of sanatorium treatment namely, prolonged bed-rest, good diet, good
airy accommodation, nursing and isolation were remarkably un-
important provided adequate chemotherapy was administered.There
have been 5 other controlled trials based on random allocation .
reported in the world medical literature which compared either sana-
torium treatment with clinic treatment (Tyrell, 1956 ; Bell, 1960) or  
rest with ambulation (Kay, 1957 ; Tuberculosis Society of Scotland,
1960; Wier et al, 1957 ; Wynn-Williams and Shaw, 1960) and not one
demonstrated any advantage either of sanatorium treatment ove
clinic treatment or of rest over ambulation. Because of these
findings and because of the gross shortage of hospital beds for tuber-
culosis, ambulatory chemotherapy for the major or the entire period
of treatment has become the accepted practice in the tuberculosis
control programmes in India as well as in many other developing
countries of the world.
Chemotherapeutic regimens.-The great progress made in the
chemotherapy of pulmonary tuberculosis during the last few years
has made it possible for the economically developed countries to treat
all newly diagnosed patients with chemotherapeutic regimens which
are potentially 100% effective.But unfortunately in our country the
most effective triple-drug regimens cannot be applied on a large scale
at present due to cost, shortage of drugs and difficulties in appli-
cation. For instance,a triple-drug regimenof streptomycin,
isoniazid and PAS given daily for 6 months followed by a dual-drug
regimen of isoniazid plus PAS for the rest of the year, although virtu-
ally 100% effective, is clearly too expensive and unsuitable for general
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A SERIES of controlled studies carried out at the Tuberculosis Chemotherapy Centre have revealed that ambulatory chemo-
2application to treat the estimated 1½ million infectious cases. Further,
there is a general shortage of all anti-tuberculosis drugs and parti-
cularly of PAS.It is therefore necessary for us, to evolve regimens
which are not only effective but also inexpensive and capable of appli-
cation on a mass scale through the existing health facilities in the
country. Let us now consider the progress we have so far made in
this direction :
At the Tuberculosis Chemotherapy Centre, Madras, a series of
controlled clinical studies based on random allocation have been
undertaken to assess the merits of different chemotherapeutic regi-
mens in the ambulatory treatment of patients with bacteriologically
confirmed pulmonary tuberculosis.Patients selected for these studies
were all drawn from the poor sections of the community in Madras
City and were referred to the Centre from the local chest clinics
where they had reported because of symptoms.They were all aged
12 years or more and were judged to be co-operative and likely to
remain in the city for a period of at least five years.They all had
newly diagnosed previously untreated (some had previous treatment
upto 2 weeks) pulmonary tuberculosis with sputum-positive on direct
smear or on culture, the great majority having advanced and cavita-
ted disease with positive direct smears.
We shall now consider the chemotherapeutic regimens studied
so far :
Daily oral regimens
plus PAS:– Isoniazid
.–Isoniazid alone compared with isoniazid
is the most effective, least toxic and least
expensive of the antituberculosis drugs, and a large body of medical
opinion had considered that isoniazid, administered by itself, was the
best available chemotherapy for developing countries.Indeed it was
being used by itself on a large scale for ambulatory treatment of
tuberculosis in India.In order to assess the value of isoniazid alone
in comparison with a standard dual drug regimen of isoniazid plu
PAS in the ambulatory treatment of pulmonary tuberculosis, a con-
trolled study based on random allocation was undertaken. In this
study 3 regimens of isoniazid alone, were compared with a standard
regimen of isoniazid plus PAS.The regimens and the daily dosages
  of drugs for a patient weighing 100 lbs. were :–
PH– Isoniazid 200 mg. plus PAS (sodium) 10 g. in 2 divided doses 
H– Isoniazid alone 200 mg. in 2 divided doses.
HI-2–  Isoniazid alone 400 mg. in 2 divided doses.
HI-1–  Isoniazid alone 400 mg. in one single dose.
The regimens and their therapeutic efficacy assessed at one year
are set out in Table I, p. 3, and it will be seen that 91% of patients
on isoniazid plus PAS attained bacteriologically quiescent disease
(i.e., all cultures, usually 3 each month, negative at 10, 11 and 12
months) at one year compared with 44%, 58% and 73%. respectively
on the 3 isoniazid alone regimens (Tuberculosis Chemotherapy
Centre, Madras, 1960). Further, it gave the first definite evidence
that isoniazid in a daily dosage of 400 mg. (approximately 9 mg./kg.
body-weight) was more effective when given in a single dose than
when given in two divided doses.This was due to the fact that in
these patients the therapeutic response was related to the peak level
of isoniazid attained in the serum rather than to the continuous
inhibitory level of the drug throughout the day (Gangadharam et al,
1961). We shall refer to this important finding again.
Since treatment with isoniazid alone in a single dose of 400 mg.
daily resulted in favourable response in 73% of patients, it was concei-
vable that increasing the single daily dose with consequent raising of
the peak level of isoniazid in the serum might improve the results
still further. Unfortunately, however, toxic manifestations of isoniazid,
principally peripheral neuropathy, occurred in 19% of patients receiving
400mg. in a single dose daily (see Table I, below) and it could be
expected to occur more frequently, if the dosage was increased.
Therefore, a double blind trial was designed principally to find an
inexpensive prophylactic for peripheral neuropathy and also to deter-
mine the therapeutic effect of increasing the single daily dose of
isoniazid. This investigation showed that a single daily dose of 650
mg. did not improve the therapeutic response attained by 400 mg. in
a single daily dose.It however, showed that as small a daily dose as
6 mg. of pyridoxine could prevent the neurological complications of
high dosage isoniazid therapy while other constituents of B complex
were practically ineffective (Tuberculosis Chemotherapy Centre,
Madras, 1963a, 1963b).
T A B L E  I
Isoniazid Study.: Daily Dosages of Drugs, Efficacy and Complications of Regimens
No. of TherapeuticChemotherapy Neuropathic
regimens doses
efficacy *
in the compli-mean a day first year cations
    200              4.4           –                      – 2 44% 0 %
Isoniazid  alone            400        8.8              –          –
(daily) 9
  400              8.8           –                         – 1 73% 19%
Isoniazid plus PAS 200  4.4
(daily) 10 0.22 2 91% 1 %
* Assessed as the percentage of patients with bacteriologically quiescent disease at 1
pear—that is, all cultures (usually 3 each month) negative at 10, 11 and 12 months.
The best available regimen of isoniazid alone is therefore clearly
inferior to the dual-drug regimen of isoniaiid plus PAS, a point
which emphasizes the need to prescribe a dual-drug regimen for all
newly diagnosed patients with positive sputum.
Isoniazid plus thioacetazone*– Since isoniazid alone even in
its optimal single daily dose is not sufficiently effective, and isoniazid
*Thioacetazone is the recommended international non-proprietary name (WHO,
1969) for 4’- formylacetanilide thiosemicarbazone (thiacetazone ; Tb1-698). .
4plus PAS is too expensive for mass application, a relatively inexpen-
sive regimen of isoniazid plus thioacetazone was compared concur-
rently with isoniazid plus PAS in a controlled trial of patients treated
at home (Tuberculosis Chemotherapy Centre, Madras, 1966).
Table II shows the two regimens and the daily dosages of drugs for
a patient weighing 100 lbs.The two regimens compared were :–
TH : Isoniazid 300 mg. (mean 6.9 mg./kg. body-weight) and thioaceta-
zone 150 mg. (mean 3.4 mg./kg. body-weight) both drugs given together in a
single dose daily.
PH: Isoniazid 200 mg. (mean 4.5 mg./kg. bodyweight) and PAS
(sodium) 10 g. (mean 0.22 g./kg. body-weight) both drugs given together in
two divided oses.
The results of treatment at one year with each regimen are set
out in Table III, below. It will be seen that the therapeutic
response was the same with both regimens.89% of patients on each
regimen attaining bacteriologically quiescent disease at one year. The
overall incidence of major toxicity was also similar in the two series
being 12% in TH and 11% in the PH series ( e Table IV, p. 5.)
However, of the 5 patients who had cutaneous hypersensitivity
T A B L E  I I
Regimens
T A B L E  I I I
Status of patients at 12 months
PAS (sodium) 10 g220 Quiescentdisease 54 8 2 53 8 2
PH plus In two Active disease 11 1 7 11 1 7
dosesIsoniazid 200 mg4.6 Death from Tuber-
Thiacetazone 150 mg3.4 In a culosis 1 2 1 2
TH plus singleIsoniazid     300    mg 6.9 dose All patients 66 100 65 100
reactions in the thioacetazone series, 3 had exfoliative dermatitis
compared with none of the 4 in the PAS series. It is therefore
important to be cautious and to withdraw the drug promptly as soon
as skin lesions occur.Hæmatological and liver function studies
did not reveal any evidence of suppression of hæmopoiesis or derange-
ment of liver function.Minor side-effects which did not require
an interruption or change of chemotherapy, such as anorexia,
vomiting, diarrhœa or giddiness occurred more commonly
in the thioacetazone series than in the PAS series. Further, the
average gain in weight and rise in the hæmoglobin level over the
year of treatment were less in the thioacetazone series than in the
PAS series. Even so, it may be concluded that thioacetazone
150 mg. plus isoniazid 300 mg. daily has emerged in this study as
an effective yet inexpensive regimen suitable for ambulatory chemo-
therapy- Further, there is evidence from East Africa (East African/
BMRC third thioacetazone investigation) that an initial supplement
of streptomycin daily for the first two months enhances its efficacy
to 90 or 93%.
Intermittent regimens.–The success of ambulatory chemo-
therapy depends almost entirely on the patient actually taking the
prescribed drugs regularly for at least one year. When daily oral
regimens are prescribed, reliance is placed on the co- peration of
patients in self-administering the drugs at home. But prolonged
self-administration of drugs often results in serious irregularities in
drug taking and consequent failure of therapy which can be prevented
only by supervising the administration of drugs. Although daily
supervision,as a general policy, is an impossible task, it may be pos-
sible to organise supervised administration of drugs intermittently
once or twice a week.
T A B L E  I V T A B L E  V
Incidence of major toxicity
(thioacetazone study) Regimens in intermittent chemotherapystudy
 PH TH    
Toxic manifestations                       Regimen SHTW PH
No. % No. %
Streptomycin 1 g.   Sodium PAS,
Cutaneous hypersensitivity 46 5 7 Drugs    (for all patients)    220 mg./kg.
Jaundice . . . ...  2 3 2 3 plus plus
Intractable vomiting         ...              2    3     2   3   dosages Isoniazid, Isoniazid,14 mg./kg. 4.5 mg./kg.                         
Total major toxicity . . . 8     11 9 12
Rhythm Twice a week Daily in
All patients in study 71 75 together two doses
As mentioned earlier, there was evidence from the is niazid   
studies that a high peak level of isoniazid in the serum each day
influenced the therapeutic response more than a continuous inhibi-
tory level of the drug in the serum throughout the day.This finding
suggested a rational basis for intermittent chemotherapy with a regi-
men containing a high dose of isoniazid in which the interval between
peak serum levels, and therefore the doses, was extended. An investi-
gation was, therefore, undertaken to assess the therapeutic efficacy of
a high dose of isoniazid in combination with another potent drug,
streptomycin, given intermittently under supervision twice a week,
the minimum interval considered to offer substantial practical advan-
tage over daily chemotherapy.This intermittent regimen was
compared concurrently with a standard oral regimen of isoniazid plus
PAS (Tuberculosis Chemotherapy Centre, Madras, 1964).
The two regimens are summarized in Table V, see above.
SHTW :–Streptomycin (Sulphate) by intramuscular injection in an uniform
dose of 1 g. (mean 27 mg./kg. body-weight) irrespective of patient’s weight, plus
isoniazid in a single oral dose of approximately 14 mg./kg. body-weight (a
patient weighing 100 lb. receiving 650 mg.) both drugs given together, under
supervision. twice weekly, at intervals of 3 and 4 days alternately.
6PH :–Isoniazid 44 mg./kg. body-weight plus PAS (sodium) 220 mg./kg. body-
weight (a patient weighing 100 lb. receiving isoniazid 200 mg. plus PAS 10 g.) the
two drugs given together in 2 divided doses daily.
Patients on the intermittent (SHTW) regimen attended the
clinic twice a week and received an injection of streptomycin and took
a dose of isoniazid under direct supervision of the clinic staff.Those
on the daily (PH) regimen attended the clinic once a week to collect a
week’s supply of the drugs which were to be taken twice daily by
themselves at home.
Over the year of treatment, the therapeutic response, in terms of
overall radiographic improvement, cavity closure and sputum conver-
sion, in the SHTW series was at least as good as in the PH series.
Thus 94% of patients on the intermittent (SHTW) regimen had bacte-
riologically-quiescent disease at one year compared with 85% on the
daily (PH) regimen(see Table VI, below).
T A B L E  V I T A B L E  V I I
Status at 1 Year Regimens
Status SHTW PH Rhythm
Drugs and dosage
Quiescent 94% 65% SHTW SHOW
Active, relapsed or 3% 14%
deteriorated
Death from TB. 3% 2 %
Streptomycin lg.
plus Twice Onceweekly weekly
Tots1 patients 72 66
Isoniazid 14 mg./kg.
Toxicity 0 3
Uncooperativeness 7 1 It may, therefore, be concluded
Non-tuberculous death 0 1 that streptomycin plus isoniazid
All patients 79 71 given together twice weekly under
    supervision has emerged in this
study as a very valuable regimen which is not only at least as effective
as a standard daily oral regimen but has the advantage that no
reliance need be placed on the co-operation of patients in self-
administering their drugs at home..This regimen, therefore, offers a
practical method of supervised chemotherapy, which is of particular
value in ambulatory chemotherapy.
Once-weekly regimens of chemotherapy.- The encouraging
results of the twice-weekly regimen suggested the possibility of a
longer interval between the doses and therefore a once weekly
regimen of isoniazid plus streptomycin has been compared with the
twice weekly regimen.
The two regimens being compared in this study are set out in
Table VII, above. In both the regimens the drugs and doses
remain the same, namely streptomycin 1 g. plus isoniazid 14 mg./kg.
body-weight, the only difference between the two being the interval
between the doses - twice weekly in one (SHTW) and once weekly
in the other (SHOW).
The interim results at 6 months, in terms of overall radiographic
improvement,cavity-closure and sputum-conversion, reaffirmed the
efficacy of the twice-weekly regimen but showed that the once-weekly
regimen was unsatisfactory. Thus, at 6 months all cultures (usually 3)
were negativein 89% of patients in the twice-weekly series as
compared with only 66% in the once-weekly series (Menon, 1965).
The failure of the once-weekly regimen in this study does not
necessarily imply that once-weekly intermittency has no therapeutic
potentialities. Indeed, there is some evidence from the interim results
of a, current study, still in progress, that the addition of a third drug
to the once-weekly regimen oran initial short course (say for
1 month) of daily chemotherapy enhances its efficacy.
These findings on the fully-supervised intermittent chemotherapy
have opened up a new approach to chemotherapy of pulmonary tuber-
culosis in general and ambulatory chemotherapy in particular, with
highly effective regimens at a relatively low cost.
Table VIII, below, summarises, the best available regimens, their
maxims1 effectiveness and the approximate cost of drugs (based
mainly on the Madras Government Medical Stores prices) for a year
of treatment.
T A B L E  V I I I
Best available regimens, maximal effectiveness and cost of drugs for one year
Regimens Drugs
Maximal
Effectiveness
%
Cost in
rupees
Triple-drug
Daily
oral
SPH (6m)—>    PH 100 269
STH (2m)—>    TH 93 59
PH 90 180
TH (?) do. 29
Dual
Drug
Inter-
mittent
S H T W   96 59
S H  ( l m )—>  SHOW (?) do.          42
Single-drug H400  70  17
Priorities of chemotherapy.–Consideringthe meagre resources
available to treat the estimated 6 million tuberoulosis patients in the
country of whom 1½ to 2 millions are in the infectious stage, the need
for a careful order of priorities is obvious.The first priority clearly
is to give effective chemotherapy for a year to all newly diagnosed
patients with active tuberculosis.The choice of the regimen would
depend upon the resources available, but the general policy should be
to choose regimens which would give the maximum benefit to the
maximum number of patients. For example; if the resources of drugs
are limited, the first priority for double-drug regimens should go to
patients whose sputum smears are positive, those nega ive on smear
being prescribed isoniazid lone in a single daily dose of 400 mg.
(approximately 9 mg./kg.) preferably with 6 mg. of pyridoxine.How-
ever, all efforts should be made to administer a double-drug regimen
for a year for every newly diagnosed patient and to educate the patient
and the family regarding the importance of regular treatment for at
least a year.The intermittent regimens would permit greeter control
over the amount of chemotherapy the patient actually receives and
ensure maximum therapeutic benefit.Th y are of particular value in
urban tuberoulosis-control progrsmmes where facilities for injections
can be organised.
Although the aim is to give chemotherapy for one year to every
patient, it is necessary to assess response to treatment by sputum
smear examination as frequently as possible, or at least at the end of
6 months of regular chemotherapy in order to decide whether or not
the same chemotherapy should be continued for the second six
months. If sputum smears are consistently positive at 6 months
after regular chemotherapy, it may be predicted with confidence that
bacteriological quiescence will not be attained with the regimen and
there will be no virtue in continuing with it and the regimen has to
be changed. On the other hand, if all smears at 6 months are negative
it can be predicted that bacteriological quiescence will be attained at
12 months if the same chemotherapy is continued up to 12 months.
T A B L E  I X      
Influence of Isoniazid on the Relapse-rate (first study)
At start of follow-up (at 19 months) Relapses in follow-up
Cavitation
status Treatment series
Isoniazid
Cavitated (200mg.for 1 year) 52 4 0
Calcium 44 8 4
Isoniazid
Non- (200mg.for 1 year) 196 1 1
Cavitated
Calcium 116 11 6
Total . . . 337 19 11
Second year of chemotherapy for patients with quiescent
disease at one year.–There is evidence from the Madras studies
that if chemotherapy is limited to one year, the likelihood of relapse
in patients with quiescent disease, over a subsequent 4-year period of
follow-up is in the order of 15% and that this can be reduced to 5% by
isoniazid alone given for the second year. There is further evidence
9that isoniazid alone given for a second year was effective in prevent-
ing almost all relapses in patients with quiescent disease who had no
residual cavitation at one year, for only 2 of 125 who received isonia-
zid for the second year had a relapse over a 4-year period of follow-up
compared with 17 of 116 who received no chemotherapy (see Table IX,
page 8). On the other hand, in patients with quiescent disease and
residual cavitation at1 year (“open negative syndrome”)
isoniazid was of doubtful value, for 4 of 52 patients who received it
had a relapse compared with 7 of 44 who received no chemotherapy
after the first year.Even if all relapses could be prevented by a
second year of combined chemotherapy, it would be unrealistic to
treat 100 patients for a second year to prevent 15 relapsing unless, as
the first priority, every newly diagnosed patient with active disease
could be also brought under effective chemotherapy.
When resources become adequate it will be logical to give a
second year of chemotherapy with isoniazid alone to those with no
residual cavitation and continue double-drug chemotherapy to
those with residual cavitation.
Reserve regimens for “failure cases.” –Reserve regimens
used for patients who fail on initial chemotherapy and have resistant
organisms, are expensive and are not available at present for use on
a large scale.The best method to tackle the drug-resistant problem
is to prevent emergence of drug-resistant organisms by giving effec-
tive chemotherapy initially, a point which underlines the need for
ensuring that patients do take the prescribed drugs regularly.
Patients who fail on thioacetazone plus isoniazid or isoniazid
alone pan be retreated with a regimen of streptomycin plus PAS
daily. The reserve regimens tested under domiciliary conditions at
this Centre for patients who failed on the initial regimens are:-
1. Streptomycin sulphate 1 g. plus pyrazinamide 1 to 1.5 g. daily.
2. Ethionamide 500 mg. plus cycloserine 500 mg. daily.
Over the year of treatment 58% of patients on each regimen
attained bacteriologically quiescent disease and toxicity was not a
serious problem with either regimen.
Summary and conclusions. –In formulating chemotherapeutic policies for
tuberculosis we have to take into consideration the availability of funds, the cost
of chemotherapy, the availability of drugs and the facilities for the application of
the regimens. Under the existing state of our medical sources. the first priority
should be to give an effective double-drug chemotherapy to every newly diagnosed
patient for one year. Irregularities in self-administration of drugs should be
prevented as far as possible by careful and repeated explanation to patients and
their families concerning the importance of regularity in drug-taking for atleast
one year.If injection facilities can be provided a supervised intermittent regimen
either preceded by a short initial course of daily chemotherapy (say for 1 month) or
for the entire period of 12 months is the best, because it permits a precise knowledge
of, and therefore greater control over the amount of chemotherapy the patient
actually receives.If the drug supply is inadequate to give a double-drug regimen
10
for all patients for a year, those with negative sputum but with clear-cut radio-
graphic evidence of active or probably active tuberculosis may be given isoniazid
alone in a single daily dose of 400 mg. (approximately 9 mg./kg.).When resources
sufficiently improve, chemotherapy with isoniazid alone may be given for the
second year for patients with quiescent disease and no residual cavitation and the
double-drug regimen continued for those wit  residual cavitation (“open negative
syndrome”).The reserve regimens are expensive, relatively more toxic and labora-
tory facilities for culture and sensitivity-testing are required to make effective use
of these regimens.
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